If you have been reading about AOD-9604 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-03-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
Founded in 1896 by Fritz Hoffmann-La Roche, the company was known early on for producing various vitamin preparations and derivatives. In 1934, it became the first company to mass-produce synthetic vitamin C, under the brand name Redoxon. During the Second World War, Roche collaborated with the Nazi regime in Germany and used forced labour in its German and Polish-based factories. It also moved all its Jewish employees to the United States to save them from Nazi attention. In 1957, Hoffmann-La Roche introduced the class of tranquilizers known as benzodiazepines (with Valium and Rohypnol being the best known members). It manufactures and sells several cancer drugs and is a leader in this field. In 1956, the first antidepressant, iproniazid, was accidentally created during an experiment while synthesizing isoniazid. Originally, it had been intended to create a more efficient drug at combatting tuberculosis. Iproniazid, however, was revealed to have its own benefits; some people felt it made them feel happier. It was withdrawn from the market in the early 1960s due to toxic side-effects. In 1976, an accident at a chemical factory in Seveso, Italy, owned by a subsidiary of Roche, caused a large dioxin contamination. In 1982, the United States arm of the company acquired Biomedical Reference Laboratories for US$163.5 million. That company dated from the late 1960s, and was located in Burlington, North Carolina. That year Hoffmann-La Roche then merged it with all of its laboratories, and incorporated the merged company as Roche Biomedical Laboratories, Inc. in Burlington.
Performance of the MasSpec Pen for ovarian cancer diagnosis was further evaluated in a report published in 2019. The authors analyzed 160 human ovarian tissue samples, including 78 normal ovary and 82 serous carcinomas, with the MasSpec Pen and developed classification models to discriminate between the normal and cancer samples. The model was able to distinguish between the normal and cancerous ovarian samples with 98.3%, 100.0%, and 92.3% overall accuracy on a training, validation, and test set of samples. Further, the report evaluated the ability of the MasSpec Pen system to distinguish ovarian cancer from fallopian tube and peritoneum tissue, two of the most common sites for ovarian cancer metastasis. Accuracies of 87.9% and 92.6% were achieved for the discrimination of cancer from fallopian tube and peritoneum tissues, respectively. The MasSpec Pen has also been implemented for the detection of pancreatic cancer during excision procedures. The MasSpec Pen was used on both ex vivo and in vivo tissue samples to discriminate between healthy pancreas and pancreatic tumor tissue. The device was also used to detect cancerous margins near adjacent structures of the pancreas such as the bile duct. The system was used in 18 pancreatic cancer surgeries and the data collected allowed the detection of cancerous tissue with high accuracy.
Ambala district: Centre of Excellence for Litchi, announced in FY2025-26. Yamunanagar district: Centre of Excellence for strawberry, announced in FY2025-26. Karnal district: Centre of Excellence for Vegetables, Gharaunda, established 7.01.2011. Karnal district: Potato Technology Centre, Shamgarh, established 06.04.2016. Kurukshetra district: Centre for Subtropical Fruits, Ladwa, established 06.04.2016. Kurukshetra district: Horticulture Integrated Bee Keeping, Ram Nagar, post office Chaduni Jattan, established 10.11.2017. Rohtak district: Hi-tech Greenhouse Seedling Centre, established 17.12.2013. Jhajjar district: Center of Excellence for Flowers, Munimpur, established 2022. Gurugram district: Hi-tech Greenhouse Seedling Centre, established 17.12.2013. Nuh district: Center of Excellence for Onions, Pinangwan, established 2022. Palwal district: Integrated Horticulture Development, Centre, Hodal, established 13.10.2018. Mahendergarh district: Integrated Horticulture Development Centre, Sundrah village on Ateli-Kanina road, established 01.09.2019. Bhiwani district: Centre of excellence for semi-arid horticulture, Gignaw, established 2022. Hisar district: Multi Crops Demonstration Centre, Barwala, established 2022. Hisar district: Date Palm and Guava Demonstration Centre, announced in FY2025-26. Fatehabad district: Guava Demonstration Centre at Government Garden Nursery on Uklana road, Bhuna, established 27.10.2020. Sirsa district: Centre of Excellence for fruits (Citrus & Pomegranate), Mangiana, established 22.06.2013.
Sources: en.wikipedia.org
== Safety challenges == Because pyrolysis takes place at high temperatures which exceed the autoignition temperature of the produced gases, an explosion risk exists if oxygen is present. Careful temperature control is needed for pyrolysis systems, which can be accomplished with pyrolysis controller. Pyrolysis also produces various toxic gases, such as carbon monoxide. The greatest risk of fire, explosion, and release of toxic gases comes when the system is starting up and shutting down, operating intermittently, or during operational upsets. Inert gas purging is essential to manage inherent explosion risks. The procedure is not trivial and failure to keep oxygen out has led to accidents.
The vacuum flask consists of two vessels, one placed within the other and joined at the neck. The gap between the two vessels is partially evacuated of air, creating a partial-vacuum which reduces heat conduction or convection. Heat transfer by thermal radiation may be minimized by silvering flask surfaces facing the gap but can become problematic if the flask's contents or surroundings are very hot; hence vacuum flasks usually hold contents below the boiling point of water. Most heat transfer occurs through the neck and opening of the flask, where there is no vacuum. Vacuum flasks are usually made of metal, borosilicate glass, foam or plastic and have their opening stoppered with cork or polyethylene plastic. Vacuum flasks are often used as insulated shipping containers. Extremely large or long vacuum flasks sometimes cannot fully support the inner flask from the neck alone, so additional support is provided by spacers between the interior and exterior shell. These spacers act as a thermal bridge and partially reduce the insulating properties of the flask around the area where the spacer contacts the interior surface. Several technological applications, such as NMR and MRI machines, rely on the use of double vacuum flasks. These flasks have two vacuum sections. The inner flask contains liquid helium and the outer flask contains liquid nitrogen, with one vacuum section in between. The loss of precious helium is limited in this way.
== Lord's Resistance Army insurgency == The United States had been involved clandestinely in the Lord's Resistance Army insurgency since at least 2008; President Barack Obama deployed forces here in October 2011, the deployment is known as Operation Observant Compass. In March 2017, NBC News reported that Green Berets have been ordered to "apprehend or remove" Joseph Kony, one of the world's most notorious warlords from the battlefield, along with his top commanders. With about 80 military personnel and several dozen support personnel they were tasked with finding around 150 LRA fighters in an area of operations the size of California; carrying out missions (specifically patrols) in the Central African Republic, Democratic Republic of the Congo, South Sudan and Uganda. The cooperation between U.S. special forces and the UPDF has led to notable successes: In January 2015, Green Berets were present after Dominic Ongwen turned himself in to authorities; previously in October 2012, an Invisible Children, Inc. program that encourages defections from the group and the rehabilitation of former fighters and escaped abductees resulted in notable defections, including several bodyguards; the LRA's "chief intelligence officer" who walked for four days from Sudan into CAR, was handed over to the UPDF with U.S. special forces present. LtCol Matt Maybouer, the commander of the operation said that "U.S. soldiers are not engaged in direct combat;" Green Beret teams conducting patrols carryout zone reconnaissance: a coordinated search for recent LRA activity.
=== Phimosis === Dorsal slit has a long history as a treatment for adult phimosis, since compared with circumcision it was relatively easy to perform, did not risk damage to the frenulum, and before the invention of antibiotics was less likely to become infected. However, the literature often indicates that despite being "a simple operation" it was "not liked by some", or refers to the "untidy apron-like appearance" it could produce. Dorsal slit has become rare in Western countries as a treatment for phimosis. Standard guidelines suggest conservative approaches first and, should those fail, either circumcision or preputioplasty to both retain the foreskin and relieve the phimosis.
Sources: en.wikipedia.org
A sizable number of Freedmen "were ignorant of the treaty clause which provided for their right of incorporation into the tribe." In the 20th century, the Cherokee Nation passed a law to limit membership to descendants of those listed as "Cherokee by blood" on the Dawes Rolls, excluding numerous African Americans and Afro-Cherokees who had been members of the tribe. In a recognition of Cherokee sovereignty, in 1989 the federal court in the Freedmen case of Nero v. Cherokee Nation held that the Cherokee Nation could legally determine its own citizenship requirements, even if that meant excluding descendants of Freedmen who had formerly been considered citizens.
== History == The compound was first extracted in impure form in 1816 by Christian Friedrich Bucholz (1770–1818). In 1873 German pharmacologist Rudolf Buchheim (1820–1879) and in 1878 the Hungarian doctor Endre Hőgyes stated that "capsicol" (partially purified capsaicin) caused the burning feeling when in contact with mucous membranes and increased secretion of gastric acid.
=== Thyroid inhibition === Perchlorate is a potent competitive inhibitor of the thyroid sodium-iodide symporter. Thus, it has been used to treat hyperthyroidism since the 1950s. At very high doses (70,000–300,000 ppb) the administration of potassium perchlorate was considered the standard of care in the United States, and remains the approved pharmacologic intervention for many countries. In large amounts perchlorate interferes with iodine uptake into the thyroid gland. In adults, the thyroid gland helps regulate the metabolism by releasing hormones, while in children, the thyroid helps in proper development. The NAS, in its 2005 report, Health Implications of Perchlorate Ingestion, emphasized that this effect, also known as Iodide Uptake Inhibition (IUI) is not an adverse health effect. However, in January 2008, California's Department of Toxic Substances Control stated that perchlorate is becoming a serious threat to human health and water resources. In 2010, the EPA's Office of the Inspector General determined that the agency's own perchlorate reference dose (RfD) of 24.5 parts per billion protects against all human biological effects from exposure, as the federal government is responsible for all US military base groundwater contamination. This finding was due to a significant shift in policy at the EPA in basing its risk assessment on non-adverse effects such as IUI instead of adverse effects.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.